Alnylam Pharmaceuticals (ALNY) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Alnylam Pharmaceuticals (ALNY) overview

Alnylam Pharmaceuticals (ALNY) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3,714m and operating profit of USD 502m; the year-end share price was 397.65 USD and market capitalisation was USD 52,639m. Alnylam Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alnylam Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 789mFY 2025
Share price397.65 USDFY 2025 year end
RevenueUSD 3,714mFY 2025
Operating profitUSD 502mFY 2025
Net earningsUSD 314mFY 2025
Market capitalisationUSD 52,639mFY 2025 year end

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company developing RNA interference therapeutics, a class of medicines designed to silence messenger RNA involved in disease. The company has six marketed RNAi-based medicines, including products commercialized by collaborators, and conducts research and clinical development across multiple programs. Its medicines address diseases including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria, serving patients through its commercial and collaborator networks.

Generate the Alnylam Pharmaceuticals report

Alnylam Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Alnylam Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Alnylam Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.